1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Sanofi Makes Case For Frontline Use Of Myeloma Drug Sarclisa

Promising Data In Newly Diagnosed Transplant-Eligible Patients

 
• By Kevin Grogan

Sarclisa, Sanofi's first in-house cancer drug to be approved since 2010, is making slow if steady progress on the sales front but remains way behind J&J's multiple myeloma behemoth Darzalex. Still, the company has been touting its case to be the anti-CD38 of choice at the ASH meeting.

Big dart
Four may be better than three when targeting multiple myeloma • Source: Alamy

Sanofi's multiple myeloma drug Sarclisa has much ground to make up on Johnson & Johnson's blockbuster Darzalex but the French major will be hoping that new data in newly diagnosed transplant-eligible patients will help bridge the gap.

The company has highlighted positive data from the Phase III HD7 trial, conducted by the German-Speaking Myeloma Multicenter Group (GMMG) and presented at the American Society of Hematology (ASH) meeting this weekend

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

China Biopharma Podcast - 14 May 2025 (Chinese Language)

 
• By Dexter Jie Yan and Xu Hu

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.

iTeos/GSK To Terminate Collaboration After TIGIT Trials Flop

 
• By Alaric DeArment

Belrestotug is the latest anti-TIGIT candidate to fail to meet expectations. iTeos said it will pursue strategic alternatives.

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

 
• By Andrew McConaghie

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe

More from Therapy Areas

iTeos/GSK To Terminate Collaboration After TIGIT Trials Flop

 
• By Alaric DeArment

Belrestotug is the latest anti-TIGIT candidate to fail to meet expectations. iTeos said it will pursue strategic alternatives.

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

 
• By Andrew McConaghie

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe